SRZN Insider Transactions
| Transaction Date (SEC Report ) |
Reporting Name | Relationship | Shrs. Owned | Type | Acq./Disp. | Shrs. Transacted | Price() | Amount() |
|---|---|---|---|---|---|---|---|---|
| 2023-03-01 | Parker Craig C | director, officer: Chief Executive Officer | 405,000 | A-Award | A | 405,000 | 1.13 | 457,650.00 |
| 2023-02-01 | Yeh Wen-Chen | officer: Chief Scientific Officer | 125,000 | A-Award | A | 125,000 | 0.70 | 87,512.50 |
| 2023-02-01 | Williams Charles O | officer: Chief Financial Officer | 125,000 | A-Award | A | 125,000 | 0.70 | 87,512.50 |
| 2022-12-15 | Parker Craig C | director, officer: Chief Executive Officer | 9,578 | A-Award | A | 9,578 | 0.41 | 3,926.98 |
| 2022-12-15 | Yeh Wen-Chen | officer: Chief Scientific Officer | 229,138 | A-Award | A | 9,578 | 0.41 | 3,926.98 |
| 2022-12-15 | Williams Charles O | officer: Chief Financial Officer | 9,578 | A-Award | A | 9,578 | 0.41 | 3,926.98 |
| 2022-12-15 | Vanhove Geertrui | officer: Chief Medical Officer | 32,412 | A-Award | A | 9,578 | 0.41 | 3,926.98 |
| 2022-12-14 | BLUTT MITCHELL J MD | 10 percent owner | 0 | S-Sale | D | 144,666 | 11.50 | 1,663,659.00 |
| 2022-12-14 | BLUTT MITCHELL J MD | 10 percent owner | 0 | S-Sale | D | 144,666 | 11.50 | 1,663,659.00 |
| 2022-10-10 | Williams Charles O | officer: Chief Financial Officer | 77,972 | A-Award | A | 77,972 | 2.16 | 168,419.52 |
| 2022-10-10 | Williams Charles O | officer: Chief Financial Officer | 2,433 | A-Award | A | 2,433 | 2.16 | 5,255.28 |
| 2022-10-10 | Williams Charles O | officer: Chief Financial Officer | 97,676 | A-Award | A | 97,676 | 2.16 | 210,980.16 |
| 2022-10-10 | Williams Charles O | officer: Chief Financial Officer | 12,164 | A-Award | A | 12,164 | 2.16 | 26,274.24 |
| 2022-10-10 | Williams Charles O | officer: Chief Financial Officer | 0 | D-Return | A | 97,676 | 5.13 | 501,077.88 |
| 2022-10-10 | Vanhove Geertrui | officer: Chief Medical Officer | 1,760 | A-Award | A | 1,760 | 2.16 | 3,801.60 |
| 2022-10-10 | Vanhove Geertrui | officer: Chief Medical Officer | 24,587 | A-Award | A | 24,587 | 2.16 | 53,107.92 |
| 2022-10-10 | Vanhove Geertrui | officer: Chief Medical Officer | 10,427 | A-Award | A | 10,427 | 2.16 | 22,522.32 |
| 2022-10-10 | Vanhove Geertrui | officer: Chief Medical Officer | 26,220 | A-Award | A | 26,220 | 2.16 | 56,635.20 |
| 2022-10-10 | Vanhove Geertrui | officer: Chief Medical Officer | 0 | D-Return | A | 1,760 | 10.77 | 18,955.20 |
| 2022-10-10 | Parker Craig C | director, officer: Chief Executive Officer | 2,065 | A-Award | A | 2,065 | 2.16 | 4,460.40 |
| 2022-10-10 | Parker Craig C | director, officer: Chief Executive Officer | 181,270 | A-Award | A | 181,270 | 2.16 | 391,543.20 |
| 2022-10-10 | Parker Craig C | director, officer: Chief Executive Officer | 315,310 | A-Award | A | 315,310 | 2.16 | 681,069.60 |
| 2022-10-10 | Parker Craig C | director, officer: Chief Executive Officer | 35,987 | A-Award | A | 35,987 | 2.16 | 77,731.92 |
| 2022-10-10 | Parker Craig C | director, officer: Chief Executive Officer | 0 | D-Return | A | 315,310 | 10.77 | 3,395,888.70 |
| 2022-10-10 | Yeh Wen-Chen | officer: Chief Scientific Officer | 29,567 | A-Award | A | 29,567 | 2.16 | 63,864.72 |
| 2022-10-10 | Yeh Wen-Chen | officer: Chief Scientific Officer | 5,562 | A-Award | A | 5,562 | 2.16 | 12,013.92 |
| 2022-10-10 | Yeh Wen-Chen | officer: Chief Scientific Officer | 0 | D-Return | A | 5,562 | 10.77 | 59,902.74 |
| 2022-07-01 | Yeh Wen-Chen | officer: Chief Scientific Officer | 500 | A-Award | A | 500 | 3.15 | 1,575.00 |
| 2022-06-07 | Kutzkey Tim | director, 10 percent owner | 20,000 | A-Award | A | 20,000 | 2.79 | 55,800.00 |
| 2022-06-07 | CHAI CHRISTOPHER Y | director | 20,000 | A-Award | A | 20,000 | 2.79 | 55,800.00 |
| 2022-06-07 | WOODHOUSE DAVID J | director | 20,000 | A-Award | A | 20,000 | 2.79 | 55,800.00 |
| 2022-06-07 | Haak-Frendscho Mary | director | 20,000 | A-Award | A | 20,000 | 2.79 | 55,800.00 |
| 2022-06-07 | Rothenberg Mace | director | 20,000 | A-Award | A | 20,000 | 2.79 | 55,800.00 |
| 2022-06-07 | Berkenblit Anna | director | 20,000 | A-Award | A | 20,000 | 2.79 | 55,800.00 |
| 2022-06-07 | Lin Shao-Lee | director | 20,000 | A-Award | A | 20,000 | 2.79 | 55,800.00 |
| 2022-03-01 | Yeh Wen-Chen | officer: Chief Scientific Officer | 125,000 | A-Award | A | 125,000 | 3.11 | 388,750.00 |
| 2022-03-01 | Vanhove Geertrui | officer: Chief Medical Officer | 125,000 | A-Award | A | 125,000 | 3.11 | 388,750.00 |
| 2022-03-01 | Williams Charles O | officer: Chief Financial Officer | 125,000 | A-Award | A | 125,000 | 3.11 | 388,750.00 |
| 2022-03-01 | Parker Craig C | director, officer: Chief Executive Officer | 370,000 | A-Award | A | 370,000 | 3.11 | 1,150,700.00 |
| 2021-08-12 | Williams Charles O | officer: Chief Financial Officer | 14,597 | A-Award | A | 14,597 | 10.25 | 149,619.25 |
| 2021-08-12 | Vanhove Geertrui | officer: Chief Medical Officer | 36,647 | A-Award | A | 36,647 | 10.25 | 375,631.75 |
| 2021-08-12 | Parker Craig C | director, officer: Chief Executive Officer | 183,335 | A-Award | A | 183,335 | 10.25 | 1,879,183.75 |
| 2021-08-11 | BLUTT MITCHELL J MD | 10 percent owner | 150,275 | A-Award | A | 107,309 | 11.50 | 1,234,053.50 |
| 2021-08-11 | BLUTT MITCHELL J MD | 10 percent owner | 432,640 | A-Award | A | 308,940 | 11.50 | 3,552,810.00 |
| 2021-08-11 | BLUTT MITCHELL J MD | 10 percent owner | 582,917 | A-Award | A | 416,250 | 11.50 | 4,786,875.00 |
| 2021-08-11 | BLUTT MITCHELL J MD | 10 percent owner | 42,966 | P-Purchase | A | 42,966 | 11.50 | 494,109.00 |
| 2021-08-11 | BLUTT MITCHELL J MD | 10 percent owner | 123,700 | P-Purchase | A | 123,700 | 11.50 | 1,422,550.00 |
| 2021-08-11 | BLUTT MITCHELL J MD | 10 percent owner | 166,667 | P-Purchase | A | 166,667 | 11.50 | 1,916,670.50 |
| 2021-08-11 | BLUTT MITCHELL J MD | 10 percent owner | 450,828 | A-Award | A | 321,928 | 0.00 | 0.00 |
| 2021-08-11 | BLUTT MITCHELL J MD | 10 percent owner | 1,297,922 | A-Award | A | 926,822 | 0.00 | 0.00 |
| 2021-08-11 | BLUTT MITCHELL J MD | 10 percent owner | 1,748,750 | A-Award | A | 1,248,750 | 0.00 | 0.00 |
| 2021-08-11 | BLUTT MITCHELL J MD | 10 percent owner | 128,900 | A-Award | A | 128,900 | 0.00 | 0.00 |
| 2021-08-11 | BLUTT MITCHELL J MD | 10 percent owner | 0 | D-Return | D | 128,900 | 0.00 | 0.00 |
| 2021-08-11 | BLUTT MITCHELL J MD | 10 percent owner | 371,100 | A-Award | A | 371,100 | 0.00 | 0.00 |
| 2021-08-11 | BLUTT MITCHELL J MD | 10 percent owner | 500,000 | A-Award | A | 500,000 | 0.00 | 0.00 |
| 2021-08-11 | Livingston Kevin Harold | other | 144,667 | A-Award | D | 144,667 | 11.50 | 1,663,670.50 |
| 2021-08-11 | Livingston Kevin Harold | other | 0 | D-Return | D | 144,667 | 11.50 | 1,663,670.50 |
| 2021-08-11 | Livingston Kevin Harold | other | 1,885,000 | A-Award | A | 1,451,000 | 0.00 | 0.00 |
| 2021-08-11 | Livingston Kevin Harold | other | 434,000 | A-Award | A | 434,000 | 0.00 | 0.00 |
| 2021-08-11 | Livingston Kevin Harold | other | 0 | D-Return | D | 144,667 | 11.50 | 1,663,670.50 |
| 2021-08-11 | Livingston Kevin Harold | other | 1,451,000 | J-Other | D | 759,000 | 0.00 | 0.00 |
| 2021-08-11 | Livingston Kevin Harold | other | 0 | D-Return | D | 144,667 | 11.50 | 1,663,670.50 |
| 2021-08-11 | Soffer Benny | other | 144,667 | A-Award | D | 144,667 | 11.50 | 1,663,670.50 |
| 2021-08-11 | Soffer Benny | other | 0 | D-Return | D | 144,667 | 11.50 | 1,663,670.50 |
| 2021-08-11 | Soffer Benny | other | 1,885,000 | A-Award | A | 1,451,000 | 0.00 | 0.00 |
| 2021-08-11 | Soffer Benny | other | 434,000 | A-Award | A | 434,000 | 0.00 | 0.00 |
| 2021-08-11 | Soffer Benny | other | 0 | D-Return | D | 144,667 | 11.50 | 1,663,670.50 |
| 2021-08-11 | Soffer Benny | other | 1,451,000 | J-Other | D | 759,000 | 0.00 | 0.00 |
| 2021-08-11 | Soffer Benny | other | 0 | D-Return | D | 144,667 | 11.50 | 1,663,670.50 |
| 2021-08-11 | Haqq Christopher | other | 0 | D-Return | D | 30,000 | 0.00 | 0.00 |
| 2021-08-11 | Haqq Christopher | other | 30,000 | A-Award | A | 30,000 | 0.00 | 0.00 |
| 2021-08-11 | Santel Donald J | other | 0 | D-Return | D | 30,000 | 0.00 | 0.00 |
| 2021-08-11 | Santel Donald J | other | 30,000 | A-Award | A | 30,000 | 0.00 | 0.00 |
| 2021-08-11 | Jarrett Jennifer | other | 0 | D-Return | D | 30,000 | 0.00 | 0.00 |
| 2021-08-11 | Jarrett Jennifer | other | 30,000 | A-Award | A | 30,000 | 0.00 | 0.00 |
| 2021-08-11 | Consonance Life Sciences | other | 144,667 | A-Award | D | 144,667 | 11.50 | 1,663,670.50 |
| 2021-08-11 | Consonance Life Sciences | other | 0 | D-Return | D | 144,667 | 11.50 | 1,663,670.50 |
| 2021-08-11 | Consonance Life Sciences | other | 1,885,000 | A-Award | A | 1,451,000 | 0.00 | 0.00 |
| 2021-08-11 | Consonance Life Sciences | other | 434,000 | A-Award | A | 434,000 | 0.00 | 0.00 |
| 2021-08-11 | Consonance Life Sciences | other | 0 | D-Return | D | 144,667 | 11.50 | 1,663,670.50 |
| 2021-08-11 | Consonance Life Sciences | other | 1,451,000 | J-Other | D | 759,000 | 0.00 | 0.00 |
| 2021-08-11 | Consonance Life Sciences | other | 0 | D-Return | D | 144,667 | 11.50 | 1,663,670.50 |
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Group doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Group or anyone involved with Discounting Cash Flows Group will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.